tbuckley/cabot-search huggingface dataset:
Rethinking Acute Respiratory Distress Syndrome after COVID-19: If a “Better” Definition Is the Answer, What Is the Question?
Authors: V. Marco Ranieri, Gordon Rubenfeld, Arthur S. Slutsky
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

The definition of acute respiratory distress syndrome (ARDS) has a somewhat controversial history, with some even questioning the need for the term "ARDS." This controversy has been amplified by the coronavirus disease (COVID-19) pandemic given the marked increase in the incidence of ARDS, the relatively new treatment modalities that do not fit neatly with the Berlin definition, and the difficulty of making the diagnosis in resource-limited settings. We propose that attempts to revise the definition of ARDS should apply the framework originally developed by psychologists and social scientists and used by other medical disciplines to generate and assess definitions of clinical syndromes that do not have gold standards. This framework is structured around measures of reliability, feasibility, and validity. Future revisions of the definition of ARDS should contain the purpose, the methodology, and the framework for empirically testing any proposed definition. Attempts to revise critical illness syndromes' definitions usually hope to make them "better"; our recommendation is that future attempts use the same criteria used by other fields in defining what "better" means.
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Authors: Koji Izutsu, Shinichi Makita, Kisato Nosaka, Makoto Yoshimitsu, Atae Utsunomiya, Shigeru Kusumoto, Satoko Morishima, Kunihiro Tsukasaki, Toyotaka Kawamata, Takaaki Ono, Shinya Rai, Hiroo Katsuya, Jun Ishikawa, Hironori Yamada, Kazunobu Kato, Masaya Tachibana, Yasuyuki Kakurai, Nobuaki Adachi, Kensei Tobinai, Kentaro Yonekura, Kenji Ishitsuka
Journal: Blood (2022)

Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent enhancer of zeste homolog 2 (EZH2) and EZH1 inhibitor, in treating relapsed or refractory (R/R) ATL. This multicenter phase 2 trial enrolled patients with R/R aggressive ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity. The primary end point was overall response rate (ORR) centrally assessed by an independent efficacy assessment committee (IEAC). Secondary end points included best response in disease compartments, duration of response (DOR), pharmacokinetics, and safety. Twenty-five patients (median age, 69.0 years) with a median of 3 prior lines of therapy were enrolled; 24 had prior mogamulizumab treatment. The primary end point was met with a centrally reviewed ORR of 48.0% (90% confidence interval [CI], 30.5-65.9), including 5 complete and 7 partial remissions. Patients pretreated with mogamulizumab had an ORR of 45.8% (4 complete and 7 partial remissions). IEAC-assessed median DOR was not reached (NR) (95% CI, 1.87 to NR; months). Treatment-emergent adverse events (TEAEs) were manageable. TEAEs that occurred in ≥20% of patients included thrombocytopenia, anemia, alopecia, dysgeusia, neutropenia, lymphopenia, leukopenia, decreased appetite, and pyrexia. Grade ≥3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL. This trial was registered at www.clinicaltrials.gov as #NCT04102150.
Microarchitectural mimicking of stroma-induced vasculature compression in pancreatic tumors using a 3D engineered model
Authors: Marcel Alexander Heinrich, Irene Uboldi, Praneeth Reddy Kuninty, Marc J.K. Ankone, Joop van Baarlen, Yu Shrike Zhang, Kartik Jain, Jai Prakash
Journal: Bioactive Materials (2022)

Fibrotic tumors, such as pancreatic ductal adenocarcinoma (PDAC), are characterized for high desmoplastic reaction, which results in high intra-tumoral solid stress leading to the compression of blood vessels. These microarchitectural alterations cause loss of blood flow and poor intra-tumoral delivery of therapeutics. Currently, there is a lack of relevant in vitro models capable of replicating these mechanical characteristics and to test anti-desmoplastic compounds. Here, a multi-layered vascularized 3D PDAC model consisting of primary human pancreatic stellate cells (PSCs) embedded in collagen/fibrinogen (Col/Fib), mimicking tumor tissue within adjunct healthy tissue, is presented to study the fibrosis-induced compression of vasculature in PDAC. It is demonstrated how the mechanical and biological stimulation induce PSC activation, extracellular matrix production and eventually vessel compression. The clinical relevance is confirmed by correlating with patient transcriptomic data. Furthermore, the effects of gradual vessel compression on the fluid dynamics occurring within the channel is evaluated in silico. Finally, it is demonstrated how cancer-associated fibroblast (CAF)-modulatory therapeutics can inhibit the cell-mediated compression of blood vessels in PDAC in vitro, in silico and in vivo. It is envisioned that this 3D model is used to improve the understanding of mechanical characteristics in tumors and for evaluating novel anti-desmoplastic therapeutics.
Piezoresistive MXene/Silk fibroin nanocomposite hydrogel for accelerating bone regeneration by Re-establishing electrical microenvironment
Authors: Zhi-Chao Hu, Jia-Qi Lu, Tai-Wei Zhang, Hai-Feng Liang, Hao Yuan, Di-Han Su, Wang Ding, Rui-Xian Lian, Yu-Xiang Ge, Bing Liang, Jian Dong, Xiao-Gang Zhou, Li-Bo Jiang
Journal: Bioactive Materials (2022)

The electrical microenvironment plays an important role in bone repair. However, the underlying mechanism by which electrical stimulation (ES) promotes bone regeneration remains unclear, limiting the design of bone microenvironment-specific electroactive materials. Herein, by simple co-incubation in aqueous suspensions at physiological temperatures, biocompatible regenerated silk fibroin (RSF) is found to assemble into nanofibrils with a β-sheet structure on MXene nanosheets, which has been reported to inhibit the restacking and oxidation of MXene. An electroactive hydrogel based on RSF and bioencapsulated MXene is thus prepared to promote efficient bone regeneration. This MXene/RSF hydrogel also acts as a piezoresistive pressure transducer, which can potentially be utilized to monitor the electrophysiological microenvironment. RNA sequencing is performed to explore the underlying mechanisms, which can activate Ca2+/CALM signaling in favor of the direct osteogenesis process. ES is found to facilitate indirect osteogenesis by promoting the polarization of M2 macrophages, as well as stimulating the neogenesis and migration of endotheliocytes. Consistent improvements in bone regeneration and angiogenesis are observed with MXene/RSF hydrogels under ES in vivo. Collectively, the MXene/RSF hydrogel provides a distinctive and promising strategy for promoting direct osteogenesis, regulating immune microenvironment and neovascularization under ES, leading to re-establish electrical microenvironment for bone regeneration.
Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology
Authors: Juan Gómez Rivas, Bhaskar Somani, Moises Rodriguez Socarrás, Giancarlo Marra, Ian Pearce, Lars Henningsohn, Patricia Zondervan, Hendrik Van Poppel, James N'Dow, Evangelos Liatsikos, Joan Palou
Journal: European Urology (2022)
Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?
Authors: Jeremiah Stamler
Journal: JAMA (1986)

The 356 222 men aged 35 to 57 years, who were free of a history of hospitalization for myocardial infarction, screened by the Multiple Risk Factor Intervention Trial (MRFIT) in its recruitment effort, constitute the largest cohort with standardized serum cholesterol measurements and long-term mortality follow-up. For each five-year age group, the relationship between serum cholesterol and coronary heart disease (CHD) death rate was continuous, gradecf, and strong. For the entire group aged 35 to 57 years at entry, the age-adjusted risks of CHD death in cholesterol quintiles 2 through 5 (182 to 202, 203 to 220, 221 to 244, and ≥245 mg/dL [4.71 to 5.22, 5.25 to 5.69, 5.72 to 6.31, and ≥6.34 mmol/L]) relative to the lowest quintile were 1.29, 1.73, 2.21, and 3.42. Of all CHD deaths, 46% were estimated to be excess deaths attributable to serum cholesterol levels 180 mg/dL or greater (≥4.65 mmol/L), with almost half the excess deaths in serum cholesterol quintiles 2 through 4. The pattern of a continuous, graded, strong relationship between serum cholesterol and six-year age-adjusted CHD death rate prevailed for nonhypertensive nonsmokers, nonhypertensive smokers, hypertensive nonsmokers, and hypertensive smokers. These data of high precision show that the relationship between serum cholesterol and CHD is not a threshold one, with increased risk confined to the two highest quintiles, but rather is a continuously graded one that powerfully affects risk for the great majority of middle-aged American men. (<i>JAMA</i>1986;256:2823-2828)
Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
Authors: Yijie Ren, Anil Kumar, Jugal K Das, Hao-Yun Peng, Liqing Wang, Darby Balllard, Xiaofang Xiong, Xingcong Ren, Yi Zhang, Jin-Ming Yang, Jianxun Song
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background T cell-mediated antitumor immunity has a vital role in cancer prevention and treatment; however, the immune-suppressive tumor microenvironment (TME) constitutes a significant contributor to immune evasion that weakens antitumor immunity. Here, we explore the relationship between nucleus accumbens-associated protein-1 (NAC1), a nuclear factor of the BTB (broad-complex, Tramtrack, bric a brac)/POZ (Poxvirus, and Zinc finger) gene family, and the TME. Methods Adoptive cell transfer (ACT) of mouse or human tumor antigen (Ag)-specific CD8 + cytotoxic T lymphocytes (CTLs) was tested in an immunocompetent or immunodeficient mouse model of melanoma with or without expression of NAC1. The effects of NAC1 expression on immune evasion in tumor cells were assessed in vitro and in vivo. CRISPR/Cas9, glycolysis analysis, retroviral transduction, quantitative real-time PCR, flow cytometric analysis, immunoblotting, database analyses were used to screen the downstream target and underlying mechanism of NAC1 in tumor cells. Results Tumorous expression of NAC1 negatively impacts the CTL-mediated antitumor immunity via lactate dehydrogenase A (LDHA)-mediated suppressive TME. NAC1 positively regulated the expression of LDHA at the transcriptional level, which led to higher accumulation of lactic acid in the TME. This inhibited the cytokine production and induced exhaustion and apoptosis of CTLs, impairing their cell-killing ability. In the immunocompetent and immunodeficient mice, NAC1 depleted melanoma tumors grew significantly slower and had an elevated infiltration of tumor Ag-specific CTLs following ACT, compared with the control groups. Conclusions Tumor expression of NAC1 contributes substantially to immune evasion through its regulatory role in LDHA expression and lactic acid production. Thus, therapeutic targeting of NAC1 warrants further exploration as a potential strategy to reinforce cancer immunotherapy, such as the ACT of CTLs.
Validation of a hand-mounted wearable sensor for scratching movements in adults with atopic dermatitis
Authors: Albert F. Yang, Keum San Chun, Lian Yu, Jessica R. Walter, Donghyun Kim, Jong Yoon Lee, Hyoyoung Jeong, Matthew C. Keller, Dhruv R. Seshadri, Matthew O. Olagbenro, Jee Won Bae, William Reuther, Ellen Wu, Kazuaki Okamoto, Akihiko Ikoma, Peter A. Lio, Anna B. Fishbein, Amy S. Paller, Shuai Xu
Journal: Journal of the American Academy of Dermatology (2022)
Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
Authors: Min Joo Choi, Ju-Yeon Choi, Hakjun Hyun, Eliel Nham, Hye Seong, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Su-Hwan Kim, Hyeonji Jeong, Min-Seong Kim, Byoungguk Kim, Joon Young Song
Journal: Journal of Infection (2022)
Transmission characteristics, replication patterns and clinical manifestations of human monkeypox virus—an in-depth analysis of four cases from Germany
Authors: Daniel Hornuss, Theo Daehne, Veronika Goetz, Matthias Mueller, Susanne Usadel, Alexandra Lorz, Maja Mockenhaupt, Daniela Huzly, Sibylle Bierbaum, Jonas Fuchs, Lena Jaki, Valeria Falcone, Georg Kochs, Marcus Panning, Siegbert Rieg
Journal: Clinical Microbiology and Infection (2022)
Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy
Authors: Sanjiv Harpavat, Kieran Hawthorne, Kenneth D. R. Setchell, Monica Narvaez Rivas, Lisa Henn, Charlotte A. Beil, Saul J. Karpen, Vicky L. Ng, Estella M. Alonso, Jorge A. Bezerra, Stephen L. Guthery, Simon Horslen, Kathy M. Loomes, Patrick McKiernan, John C. Magee, Robert M. Merion, Jean P. Molleston, Philip Rosenthal, Richard J. Thompson, Kasper S. Wang, Ronald J. Sokol, Benjamin L. Shneider
Journal: Hepatology (2022)

Background and Aims: In biliary atresia, serum bilirubin is commonly used to predict outcomes after Kasai portoenterostomy (KP). Infants with persistently high levels invariably need liver transplant, but those achieving normalized levels have a less certain disease course. We hypothesized that serum bile acid levels could help predict outcomes in the latter group. Approach and Results: Participants with biliary atresia from the Childhood Liver Disease Research Network were included if they had normalized bilirubin levels 6 months after KP and stored serum samples from the 6‐month post‐KP clinic visit ( n = 137). Bile acids were measured from the stored serum samples and used to divide participants into ≤40 μmol/L ( n = 43) or &gt;40 μmol/L ( n = 94) groups. At 2 years of age, the ≤40 μmol/L compared with &gt;40 μmol/L group had significantly lower total bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyltransferase, bile acids, and spleen size, as well as significantly higher albumin and platelet counts. Furthermore, during 734 person‐years of follow‐up, those in the ≤40 μmol/L group were significantly less likely to develop splenomegaly, ascites, gastrointestinal bleeding, or clinically evident portal hypertension. The ≤40 μmol/L group had a 10‐year cumulative incidence of liver transplant/death of 8.5% (95% CI: 1.1%–26.1%), compared with 42.9% (95% CI: 28.6%–56.4%) for the &gt;40 μmol/L group ( p = 0.001). Conclusions: Serum bile acid levels may be a useful prognostic biomarker for infants achieving normalized bilirubin levels after KP.
Gender differences in the incidence of systemic lupus erythematosus in Norway: a population-based cohort study
Authors: Hilde Haukeland, Sigrid Reppe Moe, Cathrine Brunborg, Torhild Garen, Antonela Botea, Nenad Damjanic, Gro Wivestad, Heidi Ovreaas, Thea Boe, Anniken Orre, Oyvind Molberg, Karoline Lerang
Journal: The Lancet Rheumatology (2022)
Gender equity in Brazilian rheumatology (Reuma Equity): a cross-sectional survey study
Authors: Mariana Peixoto Souza, Viviane Angelina Souza, Thais Rotsen, Maria Fernanda Guimarães, Pavel Ovseiko, Laura Coates, Grace Wright, Odirlei Monticielo, Ricardo Xavier, Adriana Kakehasi
Journal: The Lancet Rheumatology (2022)
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study
Authors: Enriqueta Vallejo-Yagüe, Julia N Pfund, Theresa Burkard, Carole Clair, Raphael Micheroli, Burkhard Möller, Axel Finckh, Andrea M Burden
Journal: The Lancet Rheumatology (2022)
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
Authors: Ashkan Shoamanesh, Hardi Mundl, Eric E Smith, Jaime Masjuan, Ivan Milanov, Teruyuki Hirano, Alina Agafina, Bruce Campbell, Valeria Caso, Jean-Louis Mas, Qiang Dong, Peter Turcani, Hanne Christensen, Jose M Ferro, Roland Veltkamp, Robert Mikulik, Gian Marco De Marchis, Thompson Robinson, Robin Lemmens, Adam Stepien, Stefan Greisenegger, Risto Roine, Laszlo Csiba, Pooja Khatri, Jonathan Coutinho, Arne G Lindgren, Andrew M Demchuk, Pablo Colorado, Bodo Kirsch, Christoph Neumann, Laura Heenan, Lizhen Xu, Stuart J Connolly, Robert G Hart
Journal: The Lancet (2022)
Gender distribution of rheumatologists across Africa (REACT): a cross-sectional survey study
Authors: Dzifa Dey, Farhanah Paruk, Girish M Mody, Asgar Kalla, Adewale Adebajo, Akpabio A Akpabio, Mohammed Hassan Abu-Zaid, Riette Du Toit, Madeleine Ngandeu-Singwe, Uhunmwangho Courage, Ouma Devi Koussougbo, Angela Migowa, Farzana Moosaaje, Hoby Nomena Rakotomalala, Mark Kaddumukasa, Ihsane Hmamouchi
Journal: The Lancet Rheumatology (2022)
Cost-Benefit Analysis of Hydrogen Breath Test–Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Authors: Alicia Muratore, Eric D. Shah, Walter W. Chan
Journal: Clinical Gastroenterology and Hepatology (2022)

Rifaximin is a Food and Drug Administration–approved, nonabsorbable antibiotic to treat diarrhea-predominant irritable bowel syndrome (IBS-D). Because of its pricing, access is often limited by step therapy requirements, meaning that insurers frequently require patients to have failed 1 or several empiric IBS-D treatments before rifaximin can be used. 1 Shah E.D. et al. Clin Gastroenterol Hepatol. 2019; 17: 2687-2695 Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar Unfortunately, rifaximin is the only Food and Drug Administration–approved IBS-D therapy that conceptually treats IBS-D mediated by small intestinal bacterial overgrowth (SIBO). As a result of limited options within the SIBO-mediated IBS-D paradigm, step therapy requirements inherently force clinicians to manage IBS-D empirically rather than using targeted-therapy based on unified pathophysiology. This problem resonates across several unique pathophysiologic mechanisms of IBS-D that each produces the common defining symptoms of abdominal pain and loose stools, including bile acid diarrhea, visceral hypersensitivity, altered intestinal permeability, and others. 2 Margolis K.G. et al. Gastroenterology. 2021; 160: 1486-1501 Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar
Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study
Authors: Xin Ni, Zhe Li, Xinping Li, Xiao Zhang, Guoliang Bai, Yingying Liu, Rongshou Zheng, Yawei Zhang, Xin Xu, Yuanhu Liu, Chenguang Jia, Huanmin Wang, Xiaoli Ma, Huyong Zheng, Yan Su, Ming Ge, Qi Zeng, Shengcai Wang, Junyang Zhao, Yueping Zeng, Guoshuang Feng, Yue Xi, Zhuo Deng, Yongli Guo, Zhuoyu Yang, Jinzhe Zhang
Journal: The Lancet (2022)
Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis
Authors: Erika Kuzminskaite, Anouk W. Gathier, Pim Cuijpers, Brenda W.J.H. Penninx, Robert T. Ammerman, Eva-Lotta Brakemeier, Sanne Bruijniks, Sara Carletto, Trisha Chakrabarty, Katie Douglas, Boadie W. Dunlop, Moritz Elsaesser, Frank Euteneuer, Anne Guhn, Elizabeth D. Handley, Erkki Heinonen, Marcus J.H. Huibers, Andrea Jobst, Gary R. Johnson, Daniel N. Klein, Johannes Kopf-Beck, Lotte Lemmens, Xiao-Wen Lu, Somaia Mohamed, Atsuo Nakagawa, Satoshi Okada, Winfried Rief, Leonardo Tozzi, Madhukar H. Trivedi, Suzanne van Bronswijk, Patricia van Oppen, Sidney Zisook, Ingo Zobel, Christiaan H. Vinkers
Journal: The Lancet Psychiatry (2022)
Characterising adults in Scotland who are not vaccinated against COVID-19
Authors: Safraj Shahul Hameed, Elliott Hall, Zoe Grange, Christopher Sullivan, Sharon Kennedy, Lewis D Ritchie, Utkarsh Agrawal, Colin R Simpson, Syed Ahmar Shah, Igor Rudan, Colin McCowan, Josephine L K Murray, Chris Robertson, Aziz Sheikh
Journal: The Lancet (2022)
Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform
Authors: Leonard Mndala, Edward J M Monk, Deborah Phiri, Jennifer Riches, Regina Makuluni, Luis Gadama, Fannie Kachale, Rosemary Bilesi, Malangizo Mbewe, Andrew Likaka, Chikondi Chapuma, Moses Kumwenda, Bertha Maseko, Chifundo Ndamala, Annie Kuyere, Laura Munthali, Marc Y R Henrion, Clemens Masesa, David Lissauer
Journal: The Lancet Global Health (2022)

Outcomes of omicron-associated COVID-19 in pregnancy have not been reported from low-resource settings, and data from sub-Saharan Africa before the emergence of omicron are scarce. Using a national maternal surveillance platform (MATSurvey), we aimed to compare maternal and neonatal outcomes of COVID-19 in Malawi during the omicron wave to the preceding waves of beta and delta.
3D engineered tissue models for studying human-specific infectious viral diseases
Authors: Kyeong Seob Hwang, Eun U Seo, Nakwon Choi, Jongbaeg Kim, Hong Nam Kim
Journal: Bioactive Materials (2022)

Viral infections cause damage to various organ systems by inducing organ-specific symptoms or systemic multi-organ damage. Depending on the infection route and virus type, infectious diseases are classified as respiratory, nervous, immune, digestive, or skin infections. Since these infectious diseases can widely spread in the community and their catastrophic effects are severe, identification of their causative agent and mechanisms underlying their pathogenesis is an urgent necessity. Although infection-associated mechanisms have been studied in two-dimensional (2D) cell culture models and animal models, they have shown limitations in organ-specific or human-associated pathogenesis, and the development of a human-organ-mimetic system is required. Recently, three-dimensional (3D) engineered tissue models, which can present human organ-like physiology in terms of the 3D structure, utilization of human-originated cells, recapitulation of physiological stimuli, and tight cell–cell interactions, were developed. Furthermore, recent studies have shown that these models can recapitulate infection-associated pathologies. In this review, we summarized the recent advances in 3D engineered tissue models that mimic organ-specific viral infections. First, we briefly described the limitations of the current 2D and animal models in recapitulating human-specific viral infection pathology. Next, we provided an overview of recently reported viral infection models, focusing particularly on organ-specific infection pathologies. Finally, a future perspective that must be pursued to reconstitute more human-specific infectious diseases is presented.
Autoimmune multimorbidity and fatigue in women with idiopathic inflammatory myopathies: an international, patient-reported, e-survey
Authors: Akira Yoshida, Minchul Kim, Masataka Kuwana, Naveen Ravichandran, Ashima Makol, Parikshit Sen, James B Lilleker, Vishwesh Agarwal, Abraham Edgar Gracia-Ramos, Albert Selva O'Callaghan, Ai Lyn Tan, Lorenzo Cavagna, Miguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta
Journal: The Lancet Rheumatology (2022)